From staff reports

FDA’s latest “Drug Info Rounds†video for health professionals helps pharmacists understand the agency’s Accelerated Approval Program for drugs when there is an unmet medical need.

It’s important to put processes in place to be sure a patient’s medication list at discharge from the hospital is the same information that is provided to the primary care physician to avoid medication errors, according to a recent study published online July 24 in The Annals of Pharmacotherapy.

FDA has issued a Drug Safety Communication concerning three children who died and one child who experienced a nonfatal but life-threatening case of respiratory depression after taking the pain-reliever codeine following tonsillectomy and/or adenoidectomy.

FDA has approved the influenza vaccine formulation for six manufacturers for the 2012-2013 influenza season.

Systemic corticosteroid monotherapy using prednisone is not effective for patients with acute rhinosinusitis, according to a new study published in the August 7 issue of the Canadian Medical Association Journal.

The use of generic prescription drugs instead of their brand-name counterparts has saved Americans and the nation’s healthcare system $1.07 trillion over 10 years ending in 2011, according to the results of a study commissioned by the Generic Pharmaceutical Association.

Federal legislation is needed to control pharmacies that are re-selling drugs on the gray market, according to Carmen Catizone, the executive director of the National Association of Boards of Pharmacy.

FDA has approved vincristine sulfate liposome injection for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) who have had at least two relapses or whose disease has progressed following two or more anti-leukemia therapies.

Jill Fitzgerald, PharmD, who is Drug Topics' CPE accreditor, was sworn in as chair-elect to the AACP Continuing Professional Education Section.

Short-term hormone replacement therapy is a relatively safe treatment for healthy, recently postmenopausal women, according to a new consensus statement.

An oral dose of modified-release tranexamic acid may offer an effective first-line therapy for patients with heavy menstrual bleeding, according to a recent study published online July 17 in The Annals of Pharmacotherapy.

A new formulation of the widely prescribed painkiller OxyContin has led drug abusers to shift to heroin, according to research results reported as a letter to the editor in the July 12 issue of the New England Journal of Medicine.

Several Congress members are concerned about the Department of Defense's use of the TRICARE mail-order pharmacy program administered by Express Scripts.

An ingestible sensor, formally referred to as the Ingestion Event Marker or IEM by Proteus Digital Health, that can report medication adherence and vital signs to physicians has been given the green light by FDA.

In a recent study, researchers found that rectal indomethacin significantly reduced the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients.

In patients with relapsing-remitting multiple sclerosis, interferon beta did not alleviate the progression of the disease, according to a new study.

More effective ways of combating pertussis in young infants, such as vaccinating pregnant women, should be considered, according to the authors of a new study.

FDA has approved ziv-aflibercept (Zaltrap, Sanofi and Regeneron Pharmaceuticals) injection for intravenous infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.

FDA approved the first generic versions of montelukast sodium (Singulair, Merck) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

Data from poison centers can be used to predict methadone overdose trends in the United States, according to a study published July 19 in PLoS One.

A recent Danish study found that exposure to the influenza A(H1N1)pdm09 vaccine during pregnancy was not associated with a significantly increased risk of major birth defects or preterm births.

FDA has announced a safety communication regarding the risk of seizures in patients with multiple sclerosis starting dalfampridine (Ampyra, Acorda Therapeutics). The safety communication stemmed from a review of post-marketing adverse event reports.

FDA has approved prednisone (Rayos, Horizon Pharma) delayed-release tablets (1 mg, 2 mg, and 5 mg) to treat a broad range of diseases including rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, and chronic obstructive pulmonary disease.

In a unanimous vote (10-0), an FDA advisory committee recommended approval of the 0.3-mg dose of ranibizumab injection (Lucentis, Genentech, a member of the Roche Group) for treatment of diabetic macular edema.

A new study has found that omega-6 fatty acids can help prevent coronary heart disease (CHD) and that dietary saturated fat increases the risk for CHD.

The Two Sister Study, funded in part by Susan Komen for the Cure, was conducted to examine the possible risks associated with fertility drugs and breast cancer. The results were published July 6 in the Journal of The National Cancer Institute.

FDA has approved aclidinium bromide inhalation powder (Tudorza Pressair, Forest Pharmaceuticals) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The National Association of Boards of Pharmacy issued a report last week that called for international collaboration among regulators and other public agencies to help combat the ongoing problem of the online counterfeit drug supply.

A new policy proposal by the Centers for Medicare and Medicaid could force independent community pharmacies to stop selling diabetes testing supplies, and beneficiaries would not have access to the care they need from their local pharmacies, according to a statement from the National Community Pharmacists Association.

FDA has approved carfilzomib (Kyprolis, Onyx Pharmaceuticals) to treat patients with multiple myeloma who have received at least 2 prior therapies, including treatment with bortezomib (Velcade, Takeda) and an immunomodulatory therapy.